NASDAQ:PLRX - Nasdaq - US7291391057 - Common Stock - Currency: USD
Taking everything into account, PLRX scores 1 out of 10 in our fundamental rating. PLRX was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of PLRX is average, but there are quite some concerns on its profitability. PLRX does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -63.67% | ||
ROE | -85.36% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.12 | ||
Debt/FCF | N/A | ||
Altman-Z | -3.74 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 11.03 | ||
Quick Ratio | 11.03 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.46
-0.06 (-3.95%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.35 | ||
P/tB | 0.35 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -63.67% | ||
ROE | -85.36% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.12 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 127.09% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 11.03 | ||
Quick Ratio | 11.03 | ||
Altman-Z | -3.74 |